No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19.
Georgia Wilson JonesMarco P MonopoliLuisa CampagnoloAntonio PietroiustiLang TranBengt FadeelPublished in: Nanomedicine (London, England) (2020)
There is an urgent need for safe and effective approaches to combat COVID-19. Here, we asked whether lessons learned from nanotoxicology and nanomedicine could shed light on the current pandemic. SARS-CoV-2, the causative agent, may trigger a mild, self-limiting disease with respiratory symptoms, but patients may also succumb to a life-threatening systemic disease. The host response to the virus is equally complex and studies are now beginning to unravel the immunological correlates of COVID-19. Nanotechnology can be applied for the delivery of antiviral drugs or other repurposed drugs. Moreover, recent work has shown that synthetic nanoparticles wrapped with host-derived cellular membranes may prevent virus infection. We posit that nanoparticles decorated with ACE2, the receptor for SARS-CoV-2, could be exploited as decoys to intercept the virus before it infects cells in the respiratory tract. However, close attention should be paid to biocompatibility before such nano-decoys are deployed in the clinic.
Keyphrases
- sars cov
- respiratory tract
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- induced apoptosis
- prognostic factors
- peritoneal dialysis
- working memory
- drug induced
- angiotensin ii
- drug delivery
- binding protein
- endoplasmic reticulum stress
- patient reported
- signaling pathway
- pi k akt